Get started
Author

Shengshan Xu

ORCID: 0000-0003-3371-7780
Observed ORCID: 0000-0003-3371-7780
OpenAlex ID: A5028892970
Interplay of disulfidptosis and the tumor microenvironment across cancers: implications for prognosis and therapeutic responses
2025 · Shengshan Xu, Zizhou Chen, et al. · BMC Cancer · 61
Antibody-drug conjugates as immuno-oncology agents in colorectal cancer: targets, payloads, and therapeutic synergies
2025 · Yihan Wang, Kai Lu, et al. · Frontiers in Immunology · 58
PDF
Discovery of PAK2 as a Key Regulator of Cancer Stem Cell in Head and Neck Squamous Cell Carcinoma Using Multi‐Omic Techniques
2025 · Puyu Wang, Shengshan Xu, et al. · Stem Cells International · 57
The Role of PLIN3 in Prognosis and Tumor-Associated Macrophage Infiltration: A Pan-Cancer Analysis
2025 · Shaohua Yang, Hejie Liu, et al. · Journal of Inflammation Research · 53
Comprehensive pan-cancer analysis reveals EPHB2 is a novel predictive biomarker for prognosis and immunotherapy response
2024 · Shengshan Xu, Youbin Zheng, et al. · BMC Cancer · 53
Targeting T cell exhaustion: emerging strategies in non-small cell lung cancer
2024 · Xianqiang Liu, Xiaowei Xi, et al. · Frontiers in Immunology · 52
PDF
A Novel Signature Integrated of Immunoglobulin, Glycosylation and Anti-Viral Genes to Predict Prognosis for Breast Cancer
2022 · Shengshan Xu, Yuchen Liu, et al. · Frontiers in Genetics · 47
Construction and validation of a hypoxia-related gene signature to predict the prognosis of breast cancer
2024 · Chaoran Qiu, Wenjun Wang, et al. · BMC Cancer · 45
PDF
Multi‑omics identification of a signature based on malignant cell-associated ligand–receptor genes for lung adenocarcinoma
2024 · Shengshan Xu, Xiguang Chen, et al. · BMC Cancer · 38
Causal association between immune cells and lung cancer risk: a two-sample bidirectional Mendelian randomization analysis
2024 · Shengshan Xu, Huiying Fang, et al. · Frontiers in Immunology · 35
Causal links between immune cells and asthma: Insights from a Mendelian Randomization analysis
2024 · Shengshan Xu, Jiahua Liang, et al. · Journal of Asthma · 34
Exploring FNDC4 as a biomarker for prognosis and immunotherapy response in lung adenocarcinoma
2024 · Shengshan Xu, Zhuming Lu · Asian Journal of Surgery · 31
JAK inhibition in PD-1 immunotherapy and tumor microenvironment
2026 · Ziyuan Liu, Jiaqi Liu, et al. · Frontiers in Immunology · 29
PDF
The role of LMNB2 as a diagnostic and prognostic biomarker in lung adenocarcinoma
2024 · Shengshan Xu, Zhuming Lu · Asian Journal of Surgery · 29
Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2
2023 · Shengshan Xu, Xiguang Chen, et al. · Frontiers in Immunology · 27
Physical Activity, Lifestyle, and Cancer Risk
2026 · Shengshan Xu, Qian Guo, et al. · JAMA Oncology · 19
Comparison of pembrolizumab plus chemotherapy versus concurrent or sequential radiochemotherapy in patients with driver mutation-lacking lung adenocarcinoma presenting with recurrent laryngeal nerve invasion leading to hoarseness.
2024 · Zhuming Lu, Shengshan Xu, et al. · Journal of Clinical Oncology · 14
PDF
Decoding tumor immune microenvironment heterogeneity by single-cell and spatial multi-omics: From immunotherapy resistance to translational biomarkers
2026 · Tingting Shi, Yanan Guo, et al. · Neoplasia · 9
PDF
Liver microenvironment-driven immunosuppressive niche in colorectal cancer liver metastasis and its therapeutic remodeling
2026 · Zijing Liu, Jia Liu, et al. · Frontiers in Immunology · 2
PDF
Editorial: Multi-omics interrogation of tumor-associated macrophages: paving the way for next-generation cancer immunotherapies
2026 · Shengshan Xu, Ke-Jie He, et al. · Frontiers in Immunology · 1
PDF
Targeted lung denervation: the imperative of phenotyping beyond airflow obstruction
2026 · Shengshan Xu, Zhichao Lin, et al. · American Journal of Respiratory and Critical Care Medicine · 1
Noninferiority in Extracorporeal Membrane Oxygenation Cannulation: A Matter of Operator, Indication, or System?
2026 · Shengshan Xu, Qian Guo, et al. · Critical Care Medicine · 1
Epigenetic regulation of cancer stem cell plasticity and relapse competence in EGFR-mutant lung cancer
2026 · Xiangxiang Sun, Shengshan Xu, et al. · Frontiers in Oncology
PDF
A Retrospective Cohort Analysis of Risk Factors for Lymph Node Metastasis in Multiple Primary Lung Cancer with 215 Cases
2026 · Tao Shen, Sisi Yang, et al. · Cancer Management and Research
PDF
Low-Dose CT Screening
2026 · Shengshan Xu, Qian Guo, et al. · CHEST Journal
PDF
Works count: 27
Citation count: 696
H-index: 16
I10-index: 17
Year
Topic
Type